Jefferies on Pharmaceuticals: Global Pharmaceuticals Q2'12 Earnings Preview; Where is it Safe to Hide?
Tweet Send to a FriendGet Alerts NVO Hot Sheet
Price: $158.76 --0%
Rating Summary:
6 Buy, 5 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 19
Rating Summary:
6 Buy, 5 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 19
Trade NVO Now!
Jefferies on Pharmaceuticals: Global Pharmaceuticals Q2'12 Earnings Preview; Where is it Safe to Hide?
Analyst, Jeffrey Holford, said, "We expect a tough earnings season as patent expiries, European pricing and FX headwinds for most companies drag on revenues and earnings. The recent macro rotation towards the sector could exacerbate the market reaction to any earnings misses in our view. We see Novo Nordisk (NYSE: NVO) and Abbott (NYSE: ABT) as the best plays on Q2'12 earnings, with AstraZeneca (NYSE: AZN), GlaxoSmithKline (NYSE: GSK), Bristol-Myers (NYSE: BMY), Novartis (NYSE: NVS) and Pfizer (NYSE: PFE) as most likely to disappoint."
Nomura maintains a 'Buy' on Abbott (NYSE: ABT), lowers PT from $76 to $75.
Maintains a 'Buy' on Bristol-Myers (NYSE: BMY), PT raised $1 to $39.
Maintains a 'Buy' on J&J (NYSE: JNJ), raises PT from $72 to $75.
Keeps 'Hold' on Eli Lilly (NYSE: LLY), PT raised $1 to $37.
Maintains a 'Hold' on Merck (NYSE: MRK), PT raised $2 to $42.
Maintains a 'Buy' on Pfizer (NYSE: PFE), PT lowered $1 to $25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jeffrey Holford, said, "We expect a tough earnings season as patent expiries, European pricing and FX headwinds for most companies drag on revenues and earnings. The recent macro rotation towards the sector could exacerbate the market reaction to any earnings misses in our view. We see Novo Nordisk (NYSE: NVO) and Abbott (NYSE: ABT) as the best plays on Q2'12 earnings, with AstraZeneca (NYSE: AZN), GlaxoSmithKline (NYSE: GSK), Bristol-Myers (NYSE: BMY), Novartis (NYSE: NVS) and Pfizer (NYSE: PFE) as most likely to disappoint."
Nomura maintains a 'Buy' on Abbott (NYSE: ABT), lowers PT from $76 to $75.
Maintains a 'Buy' on Bristol-Myers (NYSE: BMY), PT raised $1 to $39.
Maintains a 'Buy' on J&J (NYSE: JNJ), raises PT from $72 to $75.
Keeps 'Hold' on Eli Lilly (NYSE: LLY), PT raised $1 to $37.
Maintains a 'Hold' on Merck (NYSE: MRK), PT raised $2 to $42.
Maintains a 'Buy' on Pfizer (NYSE: PFE), PT lowered $1 to $25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
- Deutsche Bank Sees Upside in AIG (AIG) Stock
- Finisar (FNSR) Q4 Results 'Solid'; Est. Raised - Needham & Company
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Jefferies & Co, Nomura, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
